StreetInsider.com News Articles

bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year

Tue, 07 Jul 2026 08:46:44 -0400

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) reported that sales volume of its CyPath® Lung diagnostic test grew more than 200% year-over-year in the second quarter of 2026, according to a company press release.

The number of tests sold in Q2 2026 also increased more than 30% compared with the first quarter of 2026. The company attributed the growth to higher utilization among existing clients and a 155% increase in the number of physician offices ordering the test compared with Q2 2025.

The company said it has performed nearly 3,000 CyPath® Lung tests since the product's commercial launch. The test is used across

bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year

Tue, 07 Jul 2026 08:46:44 -0400

The company said it has performed nearly 3,000 CyPath® Lung tests since the product's commercial launch. The test is used across

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

Tue, 07 Jul 2026 08:46:00 -0400

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter

Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced continued acceleration in commercial sales for CyPath® Lung, its noninvasive lung cancer diagnostic, with

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

Tue, 07 Jul 2026 08:46:00 -0400

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter

Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

Tue, 07 Jul 2026 08:46:00 -0400

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter

Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

Tue, 07 Jul 2026 08:46:00 -0400

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter

Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

Tue, 07 Jul 2026 08:46:00 -0400

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter

Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

Tue, 07 Jul 2026 08:46:00 -0400

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter

Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025

bioAffinity Technologies reports preclinical siRNA findings for skin cancer

Mon, 22 Jun 2026 08:01:07 -0400

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has released preclinical findings showing that its small interfering RNA (siRNA) technology selectively killed squamous and basal skin cancer cells in laboratory conditions while leaving non-cancerous skin cells unharmed, according to a company press release.

The in vitro research targets two cell surface receptors, CD320 and LRP2, the silencing of which impaired cancer cell proliferation without observable harm to healthy cells. Microscopic analysis corroborated the cell viability results. The company holds U.S. Patent No. 12,305,171, issued in 2025, covering the underlying compositions and methods.

The findings have not been tested in humans, and no Investigational New

bioAffinity Technologies reports preclinical siRNA findings for skin cancer

Mon, 22 Jun 2026 08:01:07 -0400

The findings have not been tested in humans, and no Investigational New

bioAffinity Technologies reports preclinical siRNA findings for skin cancer

Mon, 22 Jun 2026 08:01:07 -0400

The findings have not been tested in humans, and no Investigational New

bioAffinity Technologies reports preclinical siRNA findings for skin cancer

Mon, 22 Jun 2026 08:01:07 -0400

The findings have not been tested in humans, and no Investigational New

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells